Systems biology of cisplatin resistance: past, present and future
L Galluzzi, I Vitale, J Michels, C Brenner… - Cell death & …, 2014 - nature.com
The platinum derivative cis-diamminedichloroplatinum (II), best known as cisplatin, is
currently employed for the clinical management of patients affected by testicular, ovarian …
currently employed for the clinical management of patients affected by testicular, ovarian …
Non-coding RNA in bladder cancer
Bladder cancer is the tenth most common cancer worldwide and has been associated with
high mortality and morbidity. Although the treatment of bladder cancer is based on well …
high mortality and morbidity. Although the treatment of bladder cancer is based on well …
The MicroRNA Expression Signature of Bladder Cancer by Deep Sequencing: The Functional Significance of the miR-195/497 Cluster
T Itesako, N Seki, H Yoshino, T Chiyomaru… - PloS one, 2014 - journals.plos.org
Current genome-wide microRNA (miRNA) expression signature analysis using deep
sequencing technologies can drive the discovery of novel cancer pathways regulated by …
sequencing technologies can drive the discovery of novel cancer pathways regulated by …
[HTML][HTML] Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury–to–chronic kidney disease progression
B Tampe, U Steinle, D Tampe, JL Carstens, P Korsten… - Kidney international, 2017 - Elsevier
Acute kidney injury (AKI) and progressive chronic kidney disease (CKD) are intrinsically tied
syndromes. In this regard, the acutely injured kidney often does not achieve its full …
syndromes. In this regard, the acutely injured kidney often does not achieve its full …
[HTML][HTML] The role of microRNAs in bladder cancer
H Enokida, H Yoshino, R Matsushita… - … and clinical urology, 2016 - synapse.koreamed.org
Bladder cancer (BC) is the fifth most common cancer worldwide and is associated with
significant morbidity and mortality. The prognosis of muscle invasive BC is poor, and …
significant morbidity and mortality. The prognosis of muscle invasive BC is poor, and …
Micro RNA expression profiling in bladder cancer: the challenge of next‐generation sequencing in tissues and biofluids
G Matullo, A Naccarati, B Pardini - International journal of …, 2016 - Wiley Online Library
Bladder cancer (BC) is a heterogeneous disease characterized by a high recurrence rate
that necessitates continuous cystoscopic surveillance. MicroRNAs (miRNAs) are detectable …
that necessitates continuous cystoscopic surveillance. MicroRNAs (miRNAs) are detectable …
The evolving understanding of microRNA in bladder cancer
Purpose Micro ribonucleic acid (miR) expression is altered in urologic malignancies,
including bladder cancer (BC). Individual miRs have been shown to modulate multiple …
including bladder cancer (BC). Individual miRs have been shown to modulate multiple …
Epigenetics of bladder cancer: where biomarkers and therapeutic targets meet
VG Martinez, E Munera-Maravilla, A Bernardini… - Frontiers in …, 2019 - frontiersin.org
Bladder cancer (BC) is the most common neoplasia of the urothelial tract. Due to its high
incidence, prevalence, recurrence and mortality, it remains an unsolved clinical and social …
incidence, prevalence, recurrence and mortality, it remains an unsolved clinical and social …
Alterations of DNA methylome in human bladder cancer
Bladder cancer is the fourth most common cancer in men in the United States, and its
recurrence rate is highest among all malignancies. The unmet need for improved strategies …
recurrence rate is highest among all malignancies. The unmet need for improved strategies …
Role of non-coding RNAs in the etiology of bladder cancer
C Gulìa, S Baldassarra, F Signore, G Rigon, V Pizzuti… - Genes, 2017 - mdpi.com
According to data of the International Agency for Research on Cancer and the World Health
Organization (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health …
Organization (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health …